Afatinib in advanced refractory urothelial cancer

Brief description of study

If you have been diagnosed with urothelial cancer (a type of bladder cancer), which cannot be removed surgically at this time and has grown after treatment with standard first-line chemotherapy containing a platinu drug, such as cisplatin or carbopiatin, you may be qualified for this study. The main goal of this study is to find out what effects the experi ental drug BIBW 2992 (also called afatinib) has on you and your advanced urothelial cancer with molecular alterations (changes in your genes) in Epidermal Growth Factor (EGF) and Human Epidermal Growth Factor Receptor (HER2) specifically, EGFR, HER2, ERBB3, or ERBB4.

Clinical Study Identifier: s17-01711 Identifier: NCT02122172

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.